Frontier Biotechnologies Management
Management criteria checks 3/4
Frontier Biotechnologies' CEO is C. J. Wang, appointed in Jan 2013, has a tenure of 12.08 years. directly owns 5.62% of the company’s shares, worth CN¥204.28M. The average tenure of the management team and the board of directors is 10.5 years and 6.4 years respectively.
Key information
C. J. Wang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.1yrs |
| CEO ownership | 5.6% |
| Management average tenure | 10.5yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO
C. J. Wang (66 yo)
12.1yrs
Tenure
CN¥2,228,000
Compensation
Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP & CFO | 9yrs | CN¥1.37m | no data | |
| CTO & Director | 12.1yrs | CN¥1.88m | 5.8% CN¥ 210.9m | |
| Supervisor & Deputy GM Administrative Director | no data | CN¥593.80k | no data | |
| Senior Vice President of Marketing & Sales | no data | CN¥1.22m | no data | |
| Deputy GM & Secretary of the Board of Directors | 4.2yrs | CN¥962.00k | no data | |
| Founder | 12.1yrs | CN¥2.26m | 3.72% CN¥ 135.0m | |
| MD, CEO & Director | 12.1yrs | CN¥2.23m | 5.62% CN¥ 204.3m | |
| Chief Operating Officer | 3.9yrs | CN¥3.47m | no data | |
| Accounting Supervisor | no data | no data | no data | |
| C.M.O. | no data | no data | no data |
10.5yrs
Average Tenure
56yo
Average Age
Experienced Management: 688221's management team is seasoned and experienced (10.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CTO & Director | 12.1yrs | CN¥1.88m | 5.8% CN¥ 210.9m | |
| Supervisor & Deputy GM Administrative Director | 6yrs | CN¥593.80k | no data | |
| Founder | 12.1yrs | CN¥2.26m | 3.72% CN¥ 135.0m | |
| MD, CEO & Director | 12.1yrs | CN¥2.23m | 5.62% CN¥ 204.3m | |
| Independent Director | 6yrs | CN¥150.00k | no data | |
| Supervisor | 6.8yrs | no data | no data | |
| Independent Director | 2.8yrs | CN¥130.20k | no data | |
| Independent Director | 6yrs | CN¥90.70k | no data | |
| Chairman of the Supervisory Board & Purchasing Director | 9yrs | CN¥380.60k | no data | |
| Director | 1yr | no data | no data |
6.4yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 688221's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 17:26 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Frontier Biotechnologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|